Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534743 | 0.89 | CRHR1 (0.35) | CRHR1KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12534731 | 0.84 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL1638189 | 0.84 | CRHR1 (0.40) | CRHR1GABRB3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5024135 | 0.84 | PTGS1 (0.41) | CRHR1KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12534773 | 0.84 | CRHR1 (0.43) | CRHR1GABRB3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1636906 | 0.83 | CRHR1 (0.39) | CRHR1GABRB3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12534721 | 0.82 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL1637198 | 0.82 | CRHR1 (0.38) | CRHR1GABRB3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12534745 | 0.81 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL12534813 | 0.81 | CRHR1 (0.52) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | CRHR1 3/4885GABRB3 1710/4885KDM4E 1303/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | CRHR1 3/4885GABRB3 1687/4885KDM4E 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.